Cover Image
Market Research Report

Febrile Neutropenia Market: By Therapeutics Molecule Type (Pegfilgrastim, Vancomycin hydrochloride, Filgrastim biosimilars, Pegfilgrastim biosimilars, Stimuxen and Others) & By Region (North America, Europe, Others)-Forecast 2019-2024

Published by IndustryARC Product code 421921
Published Content info
Delivery time: 2-3 business days
Price
Back to Top
Febrile Neutropenia Market: By Therapeutics Molecule Type (Pegfilgrastim, Vancomycin hydrochloride, Filgrastim biosimilars, Pegfilgrastim biosimilars, Stimuxen and Others) & By Region (North America, Europe, Others)-Forecast 2019-2024
Published: December 26, 2018 Content info:
Description

Febrile neutropenia is the development of fever with signs of infection and is one of the most severe complications during cancer chemotherapy. It is mainly caused by infectious agents such as gram positive and gram negative bacteria. This results in significant reduction of white blood cell count in the patients. Blood test is used to determine the number of white blood cells and to diagnose febrile neutropenia disease. Apart from blood tests, febrile neutropenia is treated through administration of prophylactic antibiotics to recover from persistent fever conditions.

The market of febrile neutropenia is majorly driven by innovative new product developments and procedures by the key players. Positive initiatives by North American and European governments will further drive the market growth of febrile neutropenia. However, lack of specific treatment for all the symptoms of this disorder may hamper the growth of this market. The market has also witnessed a high competition which eventually results in price reduction.

This report identifies the global febrile neutropenia market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global Febrile Neutropenia market.

Geographically, North America is estimated to be the largest market owing to a large pool of patients followed by Europe. It is estimated that Asia-Pacific will witness the highest growth owing to increasing awareness and new product development during the forecast period.

This report segments febrile neutropenia market on the basis of therapeutics molecule type and regional market as follows:

Febrile Neutropenia Market, by Therapeutics Molecule Type: Pegfilgrastim, Vancomycin hydrochloride, Filgrastim biosimilars, Pegfilgrastim biosimilars, Stimuxen, and Others

This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region.

Sample Companies Profiled in this Report are:

Xenetic Biosciences plc

Amgen, Inc.

Hospira, Inc.

Aequus BioPharma, Inc.

USV Limited

10+

Table of Contents

Table of Contents

1. Global Febrile Neutropenia - Market Overview

2. Executive Summary

3. Febrile Neutropenia Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
  • 3.3. Product Benchmarking
  • 3.4. End User Profiling
  • 3.5. Top 5 Financials Analysis

4. Global Febrile Neutropenia - Market Forces

  • 4.1. Drivers
    • 4.1.1. Regulations
  • 4.2. Restraints
    • 4.2.1. Lack of Specific Treatments
  • 4.3. Opportunities
    • 4.3.1. Innovations and New Product Developments
  • 4.4. Challenges
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Degree of Competition

5. Global Febrile Neutropenia Market, By Product

  • 5.1. Pegfilgrastim
  • 5.2. Vancomycin hydrochloride
  • 5.3. Filgrastim biosimilars
  • 5.4. Pegfilgrastim biosimilars
  • 5.5. Stimuxen
  • 5.6. Others

6. Global Febrile Neutropenia Market, By Geography

  • 6.1. Europe
    • 6.1.1. Germany
    • 6.1.2. France
    • 6.1.3. Italy
    • 6.1.4. Spain
    • 6.1.5. Russia
    • 6.1.6. U.K.
    • 6.1.7. Rest of Europe
  • 6.2. Asia Pacific
    • 6.2.1. China
    • 6.2.2. India
    • 6.2.3. Japan
    • 6.2.4. South Korea
    • 6.2.5. Rest of Asia-Pacific
  • 6.3. North America
    • 6.3.1. U.S.
    • 6.3.2. Canada
    • 6.3.3. Mexico
  • 6.4. Rest of the World (RoW)
    • 6.4.1. Brazil
    • 6.4.2. Rest of RoW

7. Global Febrile Neutropenia - Market Entropy

  • 7.1. Expansion
  • 7.2. Technological Developments
  • 7.3. Merger & Acquisitions, and Joint Ventures
  • 7.4. Supply- Contract

8. Company Profiles

  • 8.1. Xenetic Biosciences plc
    • 8.1.1. Introduction
    • 8.1.2. Financials
    • 8.1.3. Key Insights
    • 8.1.4. Key Strategy
    • 8.1.5. Product Portfolio
    • 8.1.6. SWOT Analysis
  • 8.2. Richter Gedeon Nyrt.
    • 8.2.1. Introduction
    • 8.2.2. Financials
    • 8.2.3. Key Insights
    • 8.2.4. Key Strategy
    • 8.2.5. Product Portfolio
    • 8.2.6. SWOT Analysis
  • 8.3. Amgen, Inc.
    • 8.3.1. Introduction
    • 8.3.2. Financials
    • 8.3.3. Key Insights
    • 8.3.4. Key Strategy
    • 8.3.5. Product Portfolio
    • 8.3.6. SWOT Analysis
  • 8.4. Hospira, Inc.
    • 8.4.1. Introduction
    • 8.4.2. Financials
    • 8.4.3. Key Insights
    • 8.4.4. Key Strategy
    • 8.4.5. Product Portfolio
    • 8.4.6. SWOT Analysis
  • 8.5. Eli Lilly and Company
    • 8.5.1. Introduction
    • 8.5.2. Financials
    • 8.5.3. Key Insights
    • 8.5.4. Key Strategy
    • 8.5.5. Product Portfolio
    • 8.5.6. SWOT Analysis
  • 8.6. USV Limited
    • 8.6.1. Introduction
    • 8.6.2. Financials
    • 8.6.3. Key Insights
    • 8.6.4. Key Strategy
    • 8.6.5. Product Portfolio
    • 8.6.6. SWOT Analysis
  • 8.7. Aequus BioPharma, Inc.
    • 8.7.1. Introduction
    • 8.7.2. Financials
    • 8.7.3. Key Insights
    • 8.7.4. Key Strategy
    • 8.7.5. Product Portfolio
    • 8.7.6. SWOT Analysis
  • 8.8. Taiho Pharmaceutical Co., Ltd.
    • 8.8.1. Introduction
    • 8.8.2. Financials
    • 8.8.3. Key Insights
    • 8.8.4. Key Strategy
    • 8.8.5. Product Portfolio
    • 8.8.6. SWOT Analysis

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

9. Appendix

  • 9.1. Abbreviations
  • 9.2. Sources
  • 9.3. Research Methodology
  • 9.4. Expert Insights
Back to Top